The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial
Crossref DOI link: https://doi.org/10.1007/s40273-015-0324-5
Published Online: 2015-09-04
Published Print: 2016-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Meads, David M.
Marshall, Andrea
Hulme, Claire T.
Dunn, Janet A.
Ford, Hugo E. R.
Text and Data Mining valid from 2015-09-04